A five-year analysis estimated disability progression at 9.4% with BRIUMVI, versus 17.9% with ofatumumab
TG Therapeutics' BRIUMVI showed lower 5-year disability progression (9.4%) vs. ofatumumab (17.9%) and ocrelizumab in a MAIC analysis, with 44% and 49% lower hazard ratios, respectively. CEO Michael S. Weiss highlighted the importance of these findings for MS treatment. The study was funded by Neuraxpharm, TG's European partner.
How this was made
The 30-second read
Why it matters
The study suggests BRIUMVI may offer superior long‑term efficacy, potentially driving demand and share price.
Market read
First public disclosure of comparative efficacy data for BRIUMVI, a material catalyst for TG Therapeutics.
What to watch
The analysis is exploratory and not a randomized trial; payer reimbursement and safety profile remain key.
Background
TG Therapeutics announced a five‑year indirect treatment comparison (MAIC) of its BRIUMVI against ocrelizumab and ofatumumab for relapsing MS.
Ticker impact
TG Therapeutics released a new five-year MAIC analysis showing BRIUMVI (ublituximab) has lower disability progression risk versus ocrelizumab and ofatumumab.
potential upside as market prices in superior efficacy data
First disclosure of head-to-head comparative outcomes, a material clinical insight for a listed biotech.
Market effects
May strengthen the anti‑CD20 segment outlook and influence competitor valuations.
US biotech sector could see modest gains on the news.
Limited to investors tracking MS therapies and biotech pipelines.
Counterpoint
Data are from a modeled indirect comparison; real-world outcomes may differ, limiting impact.
Key entities
- CompanyTG Therapeutics
Biotech firm developing BRIUMVI for multiple sclerosis.
